Trinity Capital Inc. Provides $25 Million Growth Capital to Neuros Medical, Inc.
Summary
PHOENIX, Oct. 31, 2023 /PRNewswire/ -- Trinity Capital Inc. (NASDAQ: TRIN) ("Trinity"), a leading provider of diversified financial solutions to growth-stage companies, today announced the commitment of $25 million in growth capital to Neuros Medical, Inc., a bioelectric technology company focused on alleviating chronic post-amputation pain and restoring quality of life.Neuros Medicals Altius System incorporates the companys patented platform technology, On-Demand Bioelectric Nerve Block, which patients initiate as needed for targeted pain relief. This system also has the potential to reduce drug dependency as existing treatment options are primarily limited to opioids and gabapentinoids.Rob Lake, Senior Managing Director, Life Sciences at Trinity, said, "We are proud to partner with Neuros Medical on their journey to improve the lives of those suffering from chronic post-amputation pain, and we look forward to working with their team to support their continued growth. Trinity Capital believes it is one of only a select group of specialty lenders that has the depth of knowledge, experience and track record in lending to growth stage companies. Altius incorporates the Companys patented platform technology, On-Demand Bioelectric Nerve Block. Post-amputation pain represents a significant unmet medical need, as existing treatment options are limited and consist primarily of opioids and gabapentinoids.For more information, please visit www.neurosmedical.com.